What is the appropriate treatment for Stevens‑Johnson syndrome/toxic epidermal necrolysis?

Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Immediate withdrawal of the causative drug and transfer to a specialized burn center or ICU with SJS/TEN experience (for >10% BSA involvement) is the cornerstone of treatment, followed by meticulous supportive care including wound management, fluid resuscitation, nutritional support, and pain control. 1

Immediate Actions

Drug Withdrawal

Stop the suspected culprit medication immediately—this single intervention decreases mortality risk. 2 Use the ALDEN framework to determine drug culpability during the acute phase.

Transfer to Specialized Care

Patients with >10% BSA epidermal loss must be admitted without delay to either:

• A burn center, OR
• An ICU with specific SJS/TEN management experience 1

For TEN (>30% BSA), transfer to a burn center is particularly critical if there is clinical deterioration, extension of detachment, subepidermal pus, local sepsis, or delayed healing. 1

Supportive Care Framework

Wound Management

Conservative approach (first-line):

• Cleanse wounds gently with warmed sterile water, saline, or chlorhexidine (1:5000) 1
• Apply greasy emollient (50% white soft paraffin + 50% liquid paraffin) over entire epidermis, including denuded areas; use aerosolized formulations to minimize shearing forces 1
• Apply topical antimicrobials only to sloughy areas (not prophylactically)—consider silver-containing products with caution due to absorption risk if extensive areas involved 1
• Leave detached epidermis in situ as biological dressing; decompress blisters by piercing and fluid expression 1
• Apply nonadherent dressings (Mepitel™ or Telfa™) to denuded dermis 1
• Use secondary foam/burn dressing for exudate collection (Exu-Dry™) 1

Surgical approach (if conservative fails): Consider when there is clinical deterioration, extension of detachment, subepidermal pus, local sepsis, or delayed healing:

• Debride necrotic/infected epidermis under general anesthesia using betadine or chlorhexidine 1
• Consider Versajet™ debridement 1
• Physiological closure with Biobrane/allograft/xenograft for early presentation with noninfected confluent areas 1

Infection Monitoring (Not Prophylaxis)

Critical caveat: Do NOT give prophylactic systemic antibiotics—this increases colonization with Candida albicans. 1 Only institute antimicrobials if clinical signs of infection appear.

Monitor for sepsis indicators:

• Confusion, hypotension, reduced urine output, reduced oxygen saturation
• Increased skin pain
• Rising C-reactive protein and neutrophilia
• Monoculture on swabs (previously mixed growth) indicates predominant organism and invasive infection risk 1
• Consider HSV activation in slow-healing eroded/vesicular areas (especially genital/oral sites) 1

Fluid Resuscitation

Use modified formula (NOT Parkland): body weight × % BSA epidermal detachment for volume calculation 1

Critical pitfall: Overaggressive fluid resuscitation causes pulmonary, cutaneous, and intestinal edema. SJS/TEN requires lower volumes than burn formulas predict. 1

Nutritional Support

SJS/TEN creates a hypermetabolic state with energy expenditure approximately twice the predicted resting value plus massive albumin/protein losses. 1

Enteral nutrition protocol:

• Start early via oral route or nasogastric feeding (use silicone tube if buccal mucositis present) 1
• Catabolic phase: 20-25 kcal/kg daily 1
• Anabolic/recovery phase: 25-30 kcal/kg daily 1
• Enteral preferred over parenteral to reduce peptic ulceration and bacterial translocation 1

Pain Management

Use WHO analgesic ladder principles:

• Adequate background simple analgesia for comfort at rest 1
• Add opiates (morphine-based) for moderate-to-severe pain via enteral route, patient-controlled analgesia (PCA), or infusion 1
• Caveat: Hand involvement may prevent PCA device operation 1
• Monitor consciousness level, respiratory rate, and oxygen saturation closely with opiate infusions 1

Immunomodulatory Therapy Considerations

While supportive care is universally accepted, systemic immunomodulatory therapy remains controversial with no international consensus. 3, 4, 5

Recent evidence suggests:

• Cyclosporine shows increasing evidence of effectiveness 4, 5
• Anti-TNF-α biologics (etanercept) demonstrate promising results 3, 4
• Corticosteroids remain controversial but continue as first-line in many centers 5, 6
• IVIg efficacy is inconsistent 4, 5
• Combination therapy (IVIg + corticosteroids) may be most effective for SJS/TEN overlap and TEN 5

The 2016 UK guidelines focus on supportive care without definitive immunomodulatory recommendations, reflecting the lack of high-quality evidence. [1-1]

Special Populations

Children: Infection causes up to 50% of pediatric cases (HSV, Mycoplasma pneumoniae). Test for infectious triggers and involve infectious disease specialists. 2 Manage in age-appropriate specialist units with pediatric intensivists and burn/dermatology specialists.

Malignancy/transplant patients: Worse prognosis with higher mortality; differentiate from acute GVHD. 2

Environmental Control

Maintain ambient temperature 25-28°C to reduce metabolic demands. 1